Change history
21 July 2020
The Table 2 in the original version of the above article was incorrectly presented. The data where misaligned during publication process.]
References
Westra J, Rondaan C, van Assen S, Bijl M (2015) Vaccination of patients with autoimmune inflammatory rheumatic diseases. Nat Rev Rheumatol 11:135–145
Brenol CV, Azevedo VF, Bonvehi PE, Coral-Alvarado PX, Granados J, Muñoz-Louis R, Pineda C, Vizzotti C (2018) Vaccination recommendations for adults with autoimmune inflammatory rheumatic diseases in Latin America. J Clin Rheumatol 24:138–147
Weycker D, Farkouh RA, Strutton DR et al (2016) Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions. BMC Health Serv Res 16:182
World Health Organization (2008) Position paper on 23-valent pneumococcal polysaccharide vaccine. Wkly Epidemiol Rec 83:373–384
Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B (2014) Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age. Vaccine 32:2364–2374. https://doi.org/10.1016/j.vaccine.2014.02.002
Jackson LA, Gurtman A, van Cleeff M et al (2013) Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 31:3594–3602. https://doi.org/10.1016/j.vaccine.2013.04.084
Lesprit P, Pédrono G, Molina JM et al (2007) Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 21:2425–2434. https://doi.org/10.1097/QAD.0b013e3282887e91
Centers for Disease Control and Prevention (CDC) (2012) Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep 61:816–819
Vieira de Rezende RP, Mattos GA, de Mello Leal Augusto R, Machado Gayer CR, Mendes Klumb E (2019) Predictors for seasonal influenza vaccination and reasons for inadequate vaccination coverage against a broad spectrum of vaccine-preventable diseases: a cross-sectional study among a Brazilian cohort of adult patients with systemic lupus erythematosus. Lupus 28:794–796. https://doi.org/10.1177/0961203319846383
Centers for Disease Control and Prevention (CDC) (2008) Progress in introduction of pneumococcal conjugate vaccine—worldwide, 2000-2008. MMWR Morb Mortal Wkly Rep 57:1148–1151
Ministério da Saúde (2019) Manual dos Centros de Referência para Imunobiológicos especiais (5ª edição). Ministério da Saúde https://sbim.org.br/images/calendarios/manual-centros-referencia_imunobiologicos-especiais-5ed-web.pdf Accessed on Dec 15, 2019
World Health Organization (1993) International classification of diseases and related health problems, tenth revision: volume 2, instruction manual. World Health Organization, Geneva
Sartori Vieira C, de Rezende RPV, Mendes Klumb E, Cardoso Mocarzel LO, Altenburg Gismondi R (2019) Mortality profile related to the spectrum of systemic connective tissue diseases: a retrospective, population-based, case-control study. Lupus 28:1498–1500
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
None.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
de Rezende, R.P.V., Klumb, E.M. & Pileggi, G.S. Mortality burden associated with all-cause pneumonia among adults with autoimmune inflammatory rheumatic diseases, human immunodeficiency virus infection, and malignancies: a population-based comparative study for informed decision-making in public health policies. Clin Rheumatol 39, 1703–1705 (2020). https://doi.org/10.1007/s10067-020-05039-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-020-05039-x